Alison Bryant

Articles by Alison Bryant

Global pediatric vaccine market to hit $23B by 2015

The global pediatric vaccine market will likely hit a value of more than $23 billion by 2015, a market analysis shows. GlaxoSmithKline leads the charge with nearly a quarter of the global market.

IDRI fetches $10M from Gates Foundation for adjuvant research

The Bill & Melinda Gates Foundation awarded $10 million to Seattle, WA-based IDRI for formulating new and improved vaccine adjuvants, focusing predominantly on tuberculosis.

GAVI Alliance aims to immunize 30 million girls against HPV

The GAVI Alliance wants to immunize 30 million girls worldwide with HPV vaccines by 2020.

Nuron acquires Pfizer's meningitis vaccine

Startup Nuron Biotech acquired from Pfizer a vaccine to protect against meningitis, sepsis and pneumonia for an undisclosed amount.

GSK employs mobile phones to up vaccination rates in Africa

GlaxoSmithKline will take advantage of the ubiquitous mobile phone to increase vaccination rates in Africa. The pharma giant is teaming up with British mobile phone group Vodafone to use text messages to alert mothers about the availability of vaccinations and help them to schedule appointments.

FhCMB nabs up to $9.9M from NIH for anthrax vaccine research

Fraunhofer Center for Molecular Biotechnology could receive up to $9.9 million in funding from NIH's National Institute of Allergy and Infectious Diseases to develop the next generation of anthrax vaccines.

Flu season arrives a month early

An early flu season is under way, the national Centers for Disease Control and Prevention reports, and will likely prove formidable.

DARPA tackles the DNA vaccine

After losing more than 1 million service days during the Iraq and Afghanistan wars to severe diarrhea in troops, the Defense Advanced Research Projects Agency wants to combat the problem by making drugs based on nucleic acids such as DNA rather than the weakened or dead proteins typically used in vaccines.

Protein Sciences expands flu vaccine operations to Pfizer site

Protein Sciences will lease two buildings at Pfizer's Pearl River, NY, site to create a production line for its recombinant influenza vaccine Flublok.

Altravax lands $3.45M from NIH for HIV vaccine research

North Dakota-based Altravax landed two research grants worth $3.45 million from NIH's National Institute of Allergy and Infectious Diseases for research on HIV-1 vaccines that induce antibody production.